Emerging evidence suggests impaired one-carbon metabolism in schizophrenia. Homocysteine is one of the key components of one-carbon metabolism. Elevated plasma homocysteine levels were reported in schizophrenia. A linkage study found that nicotinamide-N-methyltransferase (NNMT), an enzyme involved in one-carbon metabolism, is a determinant of plasma homocysteine levels. In an association study the rs694539 NNMT single nucleotide polymorphism (SNP) was found significantly associated with hyperhomocysteinaemia. Aiming to assess the possible involvement of NNMT in the aetiology of schizophrenia we (1) performed an association study of eight NNMT tagged SNPs in 202 families sharing the same ethnic origin including healthy parents and a schizophrenia proband ; (2) assessed NNMT mRNA levels in post-mortem frontal cortex of schizophrenia patients. Genotyping was performed using the ABI SNaPshot and the HRM methods. Individual SNPs and haplotypes were analysed for association using the family-based association test (UNPHASED software). NNMT mRNA levels were measured using RT real-time PCR. In the single SNP analysis, rs694539, previously reported to be associated with hyperhomocysteinaemia, and rs1941404 were significantly associated with schizophrenia (p<0.004 and p=0.033, respectively, following permutation test adjustment). Several haplotypes were also significantly associated with schizophrenia (global p values <0.05 following permutation test adjustment). This is the first study demonstrating an association of NNMT with schizophrenia. Post-mortem frontal cortex NNMT mRNA levels were y35 % lower in schizophrenia patients vs. control subjects. Our study favours the notion that NNMT is involved in the aetiology of schizophrenia.
Introduction
An emerging body of evidence suggests impaired onecarbon metabolism in schizophrenia (Frankenburg, 2007 ; Muntjewerff et al. 2006) . Homocysteine is one of the key components of one-carbon metabolism.
Elevated plasma homocysteine levels were reported in schizophrenia patients, particularly in young males (Akanji et al. 2007 ; Applebaum et al. 2004 ; Levine et al. 2002 ; Nevo et al. 2006 ; Regland et al. 1995) . Moreover, a recent study by Kale et al. (2009) found elevated plasma homocysteine levels accompanied by reduced plasma folate and B 12 in first-episode never-medicated schizophrenia patients. Brown et al. (2007) found that elevated maternal third-trimester serum homocysteine levels were associated with >2-fold increase in schizophrenia risk in the offspring (Weaver et al. 2007) . A meta-analysis of eight cross-sectional case-control studies suggested that a 5 mM increase in homocysteine levels is associated with a 70 % higher risk for schizophrenia (Muntjewerff et al. 2006) .
Moderately elevated plasma homocysteine levels in the range of 7.3-24.4 mM were found to be associated with human brain atrophy (Sachdev et al. 2002) and with neurotoxicity via NMDA receptors dependent on glycine levels (Lipton et al. 1997) . Homocysteine was reported to accelerate oxidative damage of endothelial cells (Lentz, 2005) and to induce mitochondrial dysfunction (Zieminska et al. 2006) . Since NMDA receptor-involved neurotoxicity (Lau & Zukin, 2007) , elevated brain cell apoptosis (Glantz et al. 2006) , mitochondrial dysfunction (Ben-Shachar, 2002 ) and hypoxia (Murray, 1994) have been reported to contribute to the pathophysiology of schizophrenia, each of the effects of homocysteine described above, or any combination of them, may be involved in the aetiology of the disorder.
Hyperhomocysteinaemia is a complex trait determined by multiple genetic and environmental factors (Carr et al. 2009 ; Malinowska & Chmurzynska, 2009 ). Methylenetetrahydrofolate reductase (MTHFR) is one of the key enzymes of one-carbon metabolism. The 677T allele of MTHFR, associated with elevated plasma homocysteine (Frosst et al. 1995) , was found to be associated with neuropsychiatric disorders including schizophrenia (Joober et al. 2000 ; Regland et al. 1997 ; Sazci et al. 2003) . Another enzyme involved in onecarbon metabolism is nicotinamide-N-methyltransferase (NNMT). NNMT methylates nicotinamide and other pyridine compounds in a reaction that transfers the methyl group released from S-adenosylmethionine (SAM) while the latter is converted into S-adenosylhomocysteine (SAH) which is further converted into homocysteine (Aksoy et al. 1994) . In addition to being the predominant route of the metabolism of nicotinamide methylation by NNMT is also an important conjugation reaction in the biotransformation of many drugs and xenobiotics (Weinshilboum, 1988) .
The NNMT gene is approximately 16.5 kb in length and consists of three exons and two introns. Fourteen tagged single nucleotide polymorphisms (SNPs) were identified across the NNMT gene. All the SNPs are located in the non-coding regions of NNMT, but they may be involved in the regulation of the gene's expression. In a genome-wide study in 398 individuals from 21 extended families, performed by Souto and colleagues to allocate chromosomal loci linked with plasma homocysteine levels, the strongest linkage signal was found on chromosome 11q23 where the NNMT gene is mapped (Souto et al. 2005) . One of ten SNPs studied (rs694539) and one haplotype were significantly associated with homocysteine levels (Souto et al. 2005) . A further study in healthy Japanese men found the same SNP to be associated with higher plasma homocysteine levels among the hyperhomocysteinaemic subgroup (Zhang et al. 2007) . Recently, two studies found an association of polymorphisms across the NNMT gene with abdominal aortic aneurism (Giusti et al. 2008) and with paediatric acute lymphoblastic leukaemia (de Jonge et al. 2009 ), disorders known to be associated with hyperhomocysteinaemia. Parkinson's disease is also associated with hyperhomocysteinaemia (Rodriguez-Oroz et al. 2009 ) and interestingly, NNMT, abundant in multiple tissues including brain (Sano et al. 1992) , was found to be overexpressed in post-mortem cerebella of Parkinson's patients (Parsons et al. 2003) .
To assess the possible involvement of the NNMT gene in the aetiology of schizophrenia we (1) performed a comprehensive association study using eight tagging SNPs spanning across the complete NNMT gene, including the SNP found to be associated with hyperhomocysteinaemia by Souto et al. (2005) , in Israeli families including a schizophrenia proband and healthy parents ; (2) measured NNMT mRNA levels in post-mortem frontal and parietal cortices of schizophrenia patients and healthy control subjects ; (3) studied whether NNMT's expression in postmortem frontal cortex of schizophrenia patients and control subjects is affected by the genotype.
Subjects and methods

Clinical samples for genotyping
For the association study DNA samples from 202 unrelated families including a schizophrenia patient and her/his parents, all of Israeli origin of the same ethnicity, were collected in two independent locations (Beer-Sheva Mental Health Center, Beer-Sheva and Emek Medical Center, Afula) after informed consent. The original protocol was approved by the Helsinki Committee (Beer-Sheva and Emek). All patients were interviewed by an experienced psychiatrist using the structural clinical interview for DSM-IV criteria (SCID). Diagnosis of schizophrenia was assigned on the basis of interview and medical records according to DSM-IV criteria (APA, 1994 Clinical samples for NNMT mRNA levels measurement NNMT mRNA levels were measured in the same postmortem frontal cortex samples (13 schizophrenia patients, 13 matched normal controls) used for genotyping.
Genotyping
DNA from peripheral lymphocytes was extracted using the phenol procedure. DNA from brain was extracted using the MasterPure TM DNA Purification kit (Epicentre, USA). SNPs were identified by searching through the dbSNP public database (http://www. ncbi.nlm.nih.gov/SNP/). Altogether 14 tagged SNPs were identified across the NNMT gene by Haploview software (http://www.broad.mit.edu/mpg/haploview/) and HapMap data (http://www.hapmap.org) using the pairwise tagging option with r 2 =0.8 as a cut-off threshold. We chose the threshold of 5 % rare allele frequency for a SNP to be included in the association study. Hence, seven SNPs were included in the study. An additional NNMT SNP (rs694539) reported by Souto et al. (2005) to be significantly associated with plasma homocysteine levels was also included in the study. The locations of the eight SNPs studied across the NNMT gene are summarized in Table 2 .
Six of the NNMT SNPs (rs4646335, rs3819100, rs2301128, rs10891645, rs2155806, rs949374) were genotyped using the SNaPshot method (Applied Biosystems, USA). This method relies upon the extension of a primer immediately adjacent to the SNP using fluorescently labelled ddNTPs. The fluorescently labelled extension primers were visualized by electrophoresis on a capillary ABI PRISM 310 automated sequencer. Two additional SNPs, rs1941404 and rs694539 were assessed by high-resolution melt (HRM) analysis, based on fluorescence tracking of DNA melting across the defined temperature range, generating melting profiles that can be used to identify the presence of single base variation within the amplicon. The pairs of primers used for the SNaPshot method and the pairs of primers used to amplify the rs1941404 and rs694539 SNPs using the HRM method are listed in Table 3. PCR cycling conditions for the SNaPshot method were as follows : samples were initially heated at 94 xC for 5 min followed by 35 cycles of 94 xC (30 s), 55 xC (30 s), 72 xC (90 s) and a final extension step of 72 xC for 5 min. After the first PCR cycle the PCR product was cleaned with ExoSAP at 37 xC for 30 min and then at 80 xC for 15 min. The conditions for the second PCR step were as follows : 96 xC (10 s), 50 xC (5 s) and 60 xC (30 s) for 25 cycles. The second PCR product was cleaned using shrimp alkaline phosphatase (SAP) initially at 37 xC for 1 h followed by 72 xC for 15 min.
PCR reactions of the HRM method were performed using 5 ml Thermo-Start Master Mix (Thermo Fisher Scientific Inc., USA), 2 ml primers (2.5 mM), 1 ml SYTO9 (dye), and 1 ml water in a total volume of 9 ml and 1 ml genomic DNA. The PCR conditions were as follows : activating enzyme step at 95 xC for 15 min, 95 xC (5 s), 58 xC (15 s) and 72 xC (10 s) for 45 cycles. The reaction proceeded to a hold at 40 xC for 2 min, a second hold at 65 xC for 2 min and then the melt procedure ramped from 75 xC to 85 xC increasing by 0.05 xC every 3 s.
For samples in which a Mendelian error occurred genotyping of the entire family was repeated. If the error persisted the family was not included in the analysis. The overall Mendelian error rate following our double-check procedure was <0.5 %.
RNA purification and cDNA synthesis RNA was purified using the RNeasy kit (Qiagen Inc., USA). RNA concentration and purity were quantified according to absorbance at 260 nm and at 280 nm (GeneQuant II ; Pharmacia Biotech, USA). The samples were treated with DNase I (RNase free) included in the kit prior to the synthesis of the cDNA to remove any genomic DNA. cDNA synthesis was performed using the Verso cDNA kit (Thermo Fisher Scientific Inc.). One mg RNA was reverse-transcribed into cDNA for 45 min at 42 xC in a final volume of 20 ml. To obtain PCR results within the linear range of detection both NNMT and b-actin cDNA products were diluted 1 : 5.
Measurement of mRNA levels by RT real-time PCR
Real-time quantitative PCR was performed using Rotor Gene 3000 (Corbett Research, Australia) using the house-keeping gene b-actin as an internal standard. b-actin has already been shown to exhibit the same level of expression in post-mortem brain of schizophrenia patients and control subjects (BenShachar & Karry, 2008) . The primers for RT-PCR were designed using primer 3 software (http://frodo.wi. mit.edu/primer3/) and verified using BLAST software to span the intron, to ensure no DNA contamination. The primers used in the reaction were as follows : NNMT forward (GTTTGGTTCTAGGCACTCTG) and reverse (GCAGGTTCTGGTCTGAGTAG) ; b-actin forward (TCCCTGGAGAAGAGCTACG) and reverse (GTAGTTTCGTGGATGCCACA).
Reactions were performed in a final volume of 25 ml consisting of 2 ml purified cDNA (NNMT or b-actin), 250 nM of each forward and reverse primers and 12.5 ml ABsolute QPCR SYBR Green Mix (ABgene, UK) providing dNTPs, Taq DNA polymerase and reaction buffer. NNMT and b-actin real-time PCR assays included an initial step of 15 min at 95 xC to activate Taq polymerase, followed by 40 cycles comprised of denaturation at 95 xC for 15 s, annealing at 58 xC for 20 s, and extension at 72 xC for 15 s. The fluorescence of the accumulating product was acquired at each cycle after an additional step of 5 s melting at 78 xC.
Quantitation of each sample was obtained by interpolation of C t values from the generated standard curve using Rotor-Gene software. All samples were run three times. The presented results are the average of the three runs. Each of the runs included a calibration curve of both b-actin and NNMT using a DNA pool which included four samples having the highest concentrations. All assays included a no template negative control.
Verification of the results of NNMT mRNA levels using three additional reference genes
RNA extraction
Total RNA was isolated from 100 mg frozen tissue using 1.0 ml TRIzol 1 reagent (Invitrogen, Australia), according to the manufacturer's instructions. The RNA was treated with DNAse I (Applied Biosystems, Australia) at 37 xC for 25-30 min, then purified by phenol/chloroform extraction and stored at x80 xC.
RNA quantity and quality were determined by spectrophotometer readings. DNA contamination was checked by PCR using primers specific for genomic DNA. First-strand cDNA was synthesized from 2 mg RNA using 100 U M-MLV-RT (Applied Biosystems) with 2.5 mM random decamers and 2.5 mM oligo dT primers (Applied Biosystems), 0.5 mM of each dNTP and 20 U RNase inhibitor in 1rRT buffer [50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 5 mM DTT] in a final volume of 20 ml. The reaction was incubated at 44 xC for 1 h then inactivated at 92 xC and the product stored at x20 xC.
Real-time PCR
Real-time reactions were performed in triplicate on cDNA template with SYBR Green detection using a Bio-Rad iQ5 Real-Time PCR detection system (Bio-Rad Laboratories, USA). The identities of the amplicons were confirmed by sequencing. Reactions were performed in 50 ml volume containing cDNA diluted 1 : 125, 0.4 nM primers and 1r IQ SYBR Green supermix (Bio-Rad Laboratories), with cycling conditions of 95 xC for 3 min, 40 cycles of 30 s each at 95 xC, 57 xC and 72 xC, followed by a melt curve. qPCR data was acquired using IQ5 optical system 2.0 software (Bio-Rad Laboratories).
Calculations
Delta C t values were calculated against a reference sample. Relative quantity was adjusted for reaction efficiencies calculated from standard curves for each gene and each plate (85-110 % efficiency range) using the Pfaffl method (Pfaffl, 2001) . Amplification levels of the target gene were normalized to the geometric mean of three reference genes : peptidylprolyl isomerase A (cyclophilin A ; PPIA), alpha synuclein (SNCA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Vandesompele et al. 2002) . (See also http://medgen.ugent.be/qbase/qBase%20manual.pdf, pages 40-44 for detailed calculations.) Reference gene primer sequences :
CycA -F : ATGGTCAACCCCACCGTGTTCTTCG, CycA -R : CGTGTGAAGTCACCACCCTGACACA, A-syn -F : CTGCTGCTGAGAAACCAAA, GAPDH -F : TGCACCACCAACTGCTTAGC, GAPDH -R : GGCATGGACTGTGGTCATGAG.
Statistical methods
We used the logistic-based variant of the transmission disequilibrium test (TDT) to assess the association without correcting for a confounding effect of population stratification. All tests were performed using the latest version (3.1.3) of the UNPHASED software for association analysis of multilocus haplotypes derived from UNPHASED genotype data (http://www.mrcbsu.cam.ac.uk/personal/frank/software/unphased/). To correct for multiple testing we used the permutation test option as provided in UNPHASED. Student's t test was used to compare post-mortem brain NNMT mRNA levels (relative to b-actin) between patients and controls.
Results
Association study
All eight NNMT-tagged SNPs genotyped (Fig. 1) were in Hardy-Weinberg equilibrium. As presented in Table 2 , single SNP analysis indicated an association with schizophrenia of two SNPs, rs1941404 in intron 2 (p=0.033) and rs694539, upstream of the NNMT gene, previously found to be associated with hyperhomocysteinaemia (Souto et al. 2005 ; Zhang et al. 2007 ) (p<0.004). We proceeded to multimarker association analysis using the sliding window approach and haplotypes comprised of consecutive 2-8 SNPs were examined. This analysis indicated a significant association with schizophrenia (adjusted by the permutation test) for several haplotypes that include one of the rs1941404 and the rs694539 SNPs or both (Table 4) . It should be noted that since the SNPs analysed were tagging SNPs selected out of all the SNPs in the NNMT gene region using Haploview and HapMap data, there is no linkage disequilibrium (LD) between the SNPs. Each of the SNPs selected reflects all the SNPs belonging to its haplotype block. This was further verified by applying Haploview software and the tagger algorithim on the results in our population ; no LD between the genotyped SNPs was revealed. As a significant global p value was obtained between certain haplotypes and schizophrenia we further examined the association of specific individual haplotypes. Individual haplotypes exhibiting significant association with schizophrenia (adjusted by permutation tests) are listed in Table 5 .
Brain mRNA levels
Post-mortem frontal cortex NNMT mRNA levels normalized for b-actin were about 35 % lower in schizophrenia patients vs. control subjects [1.3 arbitrary units (AU)¡0.6 (S.D.) vs. 2.0¡0.6, p<0.007] (Fig. 2) . To verify these results the samples were measured for NNMT levels compared to an additional three reference genes, PPIA, SNCA and GAPDH. The datasets of NNMT, PPIA, SNCA and GAPDH were shown to be normally distributed using the D'Agostino & Pearson omnibus normality test. As shown in Fig. 3 the result first obtained with b-actin as a housekeeping gene was replicated using the three other normalizing genes. Twenty-five percent statistically significant decrease in NNMT mRNA levels was obtained (1.04¡0.59 vs. 1.39¡0.04, p=0.04).
NNMT expression and genotype
There was no difference in frontal cortex NNMT mRNA levels among genotypes in either of the diagnosis groups, except for the rs949374 SNP in schizophrenia patients (ANOVA : F 1,12 =4.888, p=0.047), but this result did not remain significant after correction for multiple testing.
Discussion
This investigation is the first study reporting a genetic association between the NNMT gene and schizophrenia. Two single SNPs as well as 2-6 window-size haplotypes across the NNMT gene were significantly associated (following permutation correction for multiple testing) with schizophrenia. The rs694539 SNP, located upstream of the NNMT gene, has previously been found to be associated with elevated plasma homocysteine levels in 398 Spanish subjects (Souto et al. 2005) and with higher plasma homocysteine levels in a hyperhomocysteinaemic subgroup of healthy Japanese men (Zhang et al. 2007) . Earlier studies carried out in human liver biopsies (Smith et al. 1998 ; Yan et al. 1999) detected no SNPs or insertion/ deletion events within either the exons or the 5k-flanking region of NNMT. The authors did find eight SNPs within intron 1, none of which was related to the level of NNMT activity, but these SNPs were other than those studied by us. Smith et al. (1998) found phenotypic differences in NNMT activity in the general population but no cDNA transcript differences among subjects with low, intermediate and high NNMT activity. They concluded that the activity differences stem from differences in mRNA steady-state levels. The authors note that differences in steady-state mRNA levels may relate to the rate of its synthesis or its catabolism and suggest that differences in the NNMT's gene transcription rate may be due to differences in regulatory regions of the gene resulting in different enzymatic activity.
Plasma homocysteine levels were not available for the DNA samples of our cohort, but schizophrenia is strongly associated with hyperhomocysteinaemia (Akanji et al. 2007 ; Kale et al. 2009 ; Levine et al. 2005b ; Muntjewerff et al. 2006) . Interestingly, two groups have recently reported association of NNMT with additional hyperhomocysteinemia-related disorders. Giusti et al. (2008) found an association between NNMT and abdominal aortic aneurism and de Jonge (2009) found an association between NNMT and paediatric acute lymphoblastic leukaemia. Post-mortem frontal cortex NNMT mRNA levels were about 30 % decreased in schizophrenia patients. The finding does not simplistically correlate with hyperhomocysteinaemia reported in this disorder. It has previously been reported that treatment with an NNMT inhibitor resulted in reduced rather than increased homocysteine release (Riederer et al. 2009 ). Since homocysteine cycles through methylationdemethylation reactions (from homocysteine to methionine, to SAM, to SAH and back to homocysteine) it is difficult to predict whether increased or decreased NNMT activity would lead to hyperhomocysteinaemia.
The NNMT SNPs included in the haplotypes found now to be associated with schizophrenia are located either in introns or upstream of the coding region and are therefore not translated. However, the possibility that these SNPs may have a regulatory role in the transcription of the gene and could account for the reduced mRNA levels cannot be ruled out. We therefore correlated NNMT genotype to its expression in post-mortem frontal cortex samples. No correlation was found. This might have resulted from the very small sample size of the post-mortem samples, possibly reflecting a type II error.
Cerebrospinal fluid (CSF) homocysteine levels are about 2-fold lower than those in plasma but there are controversies whether CSF and plasma homocysteine levels correlate (Levine et al. 2005a ; Obeid et al. 2007 ; Valentino et al. 2010) . Given the neurotoxic effect of high homocysteine (Bisschops et al. 2004 ; Lipton et al. 1997 ; Zieminska et al. 2006) it is of interest that elevated CSF homocysteine levels have recently been found in neurodegenerative diseases such as Alzheimer's disease (Isobe et al. 2009 (Isobe et al. , 2005 ), Parkinson's disease (Postuma & Lang, 2004) and amyotrophic lateral sclerosis (ALS) (Valentino et al. 2010 ). In the ALS study both plasma and CSF homocysteine levels were elevated but no correlation between the two variables was found. This may suggest that CSF homocysteine originates directly in the central nervous system. If this is the case it is tempting to speculate that decreased frontal cortex NNMT expression is related to elevated homocysteine levels in this brain region resulting in exacerbated neuronal damage.
The present study suffers from two central limitations : (a) our association study cohort consisted of a relatively small sample size ; (b) the SNPs included in the haplotypes found to be associated with schizophrenia are located either in introns or upstream of the coding region and are therefore not translated, questioning their functional implication.
Our study supports the involvement of NNMT in the aetiology of schizophrenia but awaits replication in additional populations. Further investigation of the relationship between NNMT polymorphisms and expression and between NNMT expression and plasma and CSF homocysteine levels are warranted. Fig. 3 . Bar graph demonstrating significantly lower frontal cortex NNMT mRNA levels in schizophrenia patients vs. controls using PPIA, SNCA and GAPDH as normalizing genes. t test, * p=0.04. &, Controls ; %, schizophrenia.
